TriSalus Life Sciences, Inc.
corporate_fare Company Profile
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for TLSI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for TLSI spans 4, 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- CEO Mary Szela Buys 65,192 TriSalus Shares for $160,205
- TriSalus 10-Q: Q3 Revenue $12.9M, Net Loss Narrows to $8.9M, $41.1M Cash
- TriSalus Q3 Revenue $12.9M; 2026 Guidance Cut to $46-48M as CMS Boosts PEDD Reimbursement
- TriSalus Q3 Revenue Up 11% but 2026 Guidance Cut to 2-6% Growth
- FDA Clears TriSalus' TriNav Advance, Expanding PEDD Portfolio for Liver Embolization
Financial Snapshot
Short Interest & Short Volume
28.45 days to coverFINRA reported short interest of 3,312,552 shares in TLSI as of the October 30, 2026 settlement, a 3.8% decrease from the prior period — about 28.4 days to cover at its recent average daily volume. On November 20, 2026, 58.0% of TLSI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.